Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ambo Innovations LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, PRAGANI, RAJAN, in 1 distinct art unit. PRAGANI, RAJAN is the busiest examiner with 1 pending office action. This single action represents the entirety of the company's current pending workload at the USPTO.
The prosecution of this 1 pending office action is being conducted by PRAGANI, RAJAN within 1 distinct art unit. Practitioners should focus on the examiner's specific approach to Biotechnology & Pharmaceuticals technology area patents. Because there are no other pending office actions, the company's resources can be entirely focused on this one matter. The success of the company's current patent strategy hinges on the outcome of this 1 pending office action, making the interaction with the assigned examiner the central focus of their prosecution activity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRAGANI, RAJAN | 1 | 52.4% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864389 | TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D | PRAGANI, RAJAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864389 | TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D | PRAGANI, RAJAN | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864389 | TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D | PRAGANI, RAJAN | 1614 | §101§103§112DP | Non-Final OA | — | Pending | Nov 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmbo Innovations LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rajan Pragani has the most, with 1 of Ambo Innovations LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
